KN

KN (Knowles Corporation) Analyst Note

Date: 2026-06-13 Subject: Structural Setup & Business Thesis Review

1. Structural Readiness

• State: Actionable (Forming Coil)
• Conservative Entry: Not yet triggered (awaiting breakout above the coil high).
• Aggressive/Pre-Breakout Entry: Not applicable for this specific setup classification; the current price is within the consolidation range.
• Breakout Level: Not yet established (requires price to close above the coil high).
• Current Price: $41.37.
• Extension: Not applicable (price is within the coil range, not extended above the breakout).
• ATR Context: Current ATR is 4.1% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural setups, suggesting sufficient momentum to potentially drive a breakout once triggered, but also implying wider stop-loss requirements if the setup fails.

2. Thesis Layer

• Primary Secular Thesis: Defense Modernization (C4ISR / Sensors / EW).
• Role & Directness: Knowles is a tertiary beneficiary in this theme. The company supplies high-performance RF filters and capacitors critical for radar systems, satellite communications, and general communications equipment within defense platforms. While not a prime contractor, the "extreme reliability" and "custom engineering" of its Precision Devices (PD) segment are essential for the C4ISR ecosystem.
• Secondary Secular Themes:
• Energy Transition & Electrification: Also a tertiary beneficiary. The PD segment is seeing growth in specialty film capacitors for power applications, driven by the emergence of alternative technologies in the EV supply chain and energy sectors.
• Medtech & Aging Population: A strong, direct beneficiary. The MSA segment is positioned to capture volume growth from hearing health solutions, driven by demographic shifts and regulatory changes (OTC hearing aids).
• Conviction Weighting: The name rides a "triple wave" of structural tailwinds. While the Defense and Electrification themes are tertiary, the Medtech theme is a direct volume driver. The combination of a robust backlog in PD (1.19 book-to-bill) and strong growth in MSA suggests the company is successfully executing across multiple secular cycles simultaneously, providing a diversified revenue base that supports the "Margin Inflector" archetype.

3. The Business

Knowles Corporation operates as a specialized manufacturer of electronic components, serving diverse industries including consumer electronics, medical technology, defense, and industrial applications. The company operates through two distinct segments:

• Precision Devices (PD): Accounts for 55% of consolidated revenues (FY2025). This segment manufactures high-performance capacitors (including specialty film) and RF solutions.
• *Evidence:* In Q1 2026, PD revenues reached $85 million, up 17% year-over-year. The segment saw growth across all end markets: Medtech, Defense, Industrial, and Electrification.
• *Ordering:* The book-to-bill ratio for PD was 1.19 in Q1 2026, marking the sixth consecutive quarter where the ratio exceeded 1.0, indicating strong demand visibility.
• Microphone & Specialty Audio (MSA): Accounts for 45% of consolidated revenues (FY2025). This segment produces micro-acoustic microphones, balanced armature speakers, and audio processors.
• *Evidence:* In Q1 2026, MSA revenues were $68 million, up 14% year-over-year. Growth was driven by new product introductions and strong positioning on platforms in the hearing health market.
• Business Model: The company sells directly to OEMs, contract manufacturers, and suppliers, as well as through a network of distributors.
• *Customer Concentration:* MSA relies on a limited number of customers (top 5 accounted for 76% of segment revenue in 2025), with WS Audiology A/S being a significant contributor. PD relies on a distributor network, with TTI, Inc. representing 19% of PD revenues in 2025.
• Financial Performance:
• Total Q1 2026 revenue was $153.1 million, up 15.8% from $132.2 million in Q1 2025.
• Adjusted EBIT for Q1 2026 was $30.1 million, compared to $21.7 million in Q1 2025, an increase of $8.4 million.

4. Archetype and Conviction

• Archetype: Margin Inflector.
• Fit: The company is transitioning from a volume-growth phase to a profitability-growth phase. Management explicitly stated confidence in improving gross margins in the PD segment by 100 basis points in the back half of 2026, driven by the ramp-up of new capacity and yield improvements.
• Evidence: Management noted that a $25 million-plus revenue contribution from new capacity is expected at "pretty good gross margins" for the rest of the year. The Q1 EBIT expansion ($8.4M increase) supports the narrative of operating leverage kicking in.
• Valuation Context:
• Forward consensus EPS for FY1 is $1.2925, and for FY2 is $1.5575.
• The current price of $41.37 implies a forward P/E of approximately 32x for FY1 and 26.5x for FY2. Given the 15.8% revenue growth and the expected margin expansion, the valuation appears to be pricing in a successful execution of the margin inflection thesis.
• Conviction Stack:
• Thesis Strength: High. The company is exposed to three distinct secular growth drivers (Defense, Electrification, Medtech).
• Evidence Quality: Strong. Q1 2026 results show double-digit growth in both segments, a book-to-bill > 1.0, and significant EBIT expansion.
• Structural Quality: The "Margin Inflector" archetype is supported by concrete management guidance on yield and capacity ramp.
• Rerating Potential: Moderate to High. If the margin expansion targets are met, the multiple could expand as the market re-rates the company from a pure growth story to a high-quality compounder with improving profitability.

5. Invalidations, Strengths, and Gaps

• What Would Invalidate:
• A significant deterioration in the PD book-to-bill ratio (falling below 1.0) would signal a breakdown in the primary growth engine.
• Failure to achieve the targeted 100 basis point gross margin improvement in the back half of 2026 would undermine the "Margin Inflector" thesis.
• What Would Strengthen:
• A confirmed breakout above the coil high, accompanied by volume.
• Further confirmation of the $25 million-plus revenue contribution from new capacity with realized high gross margins.
• Expansion of the book-to-bill ratio in PD beyond 1.19.
• Gaps in Evidence:
• Specific Capacity Ramp Details: While management mentions a $25 million contribution, the specific timeline for the full ramp and the exact gross margin percentage of this new capacity are not detailed in the provided evidence.
• Customer Concentration Risk Mitigation: The heavy reliance on WS Audiology (24% of MSA revenue) and TTI (19% of PD revenue) is noted, but there is no evidence in the provided text regarding diversification efforts or contract terms that might mitigate this risk.
• CD Business Costs: Evidence mentions "higher costs in our CD business specialty film line" as a headwind, but the magnitude of this impact on overall margins is not quantified in the provided snippets.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Q1 2026 revenue growth of 15.8% with 17% growth in the dominant PD segment; PD book-to-bill of 1.19 for the sixth consecutive quarter; management guidance for 100 bps gross margin expansion in PD in H2 2026. Key risks: High customer concentration in MSA (WS Audiology) and PD (TTI); elevated volatility (4.1% ATR) increasing execution risk; potential margin pressure from CD business ramp-up costs. Sizing hint: Position size should reflect the "forming" nature of the setup; allocate based on the conviction in the margin inflection thesis rather than the technical breakout. Expected path: Management expects revenue growth to exceed the high end of the 4-6% target range, with PD margins expanding as new capacity ramps. The stock likely consolidates near current levels until a confirmed breakout or further margin guidance is released. Expected horizon: 6 to 12 months, aligned with the back-half 2026 margin ramp and full-year 2026 results.